Salidroside Reduces Cell Mobility via NF- κ B and MAPK Signaling in LPS-Induced BV2 Microglial Cells

Haixia Hu1, Zuanfang Li1, Xiaoqin Zhu1

  • 1Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Huatuo Road, Minhou Shangjie, Fuzhou, Fujian 350108, China ; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Huatuo Road, Minhou Shangjie, Fuzhou, Fujian 350108, China.

Insights

Salidroside effectively inhibits microglial cell migration and reduces inflammatory chemokines by suppressing NF-κB and MAPK pathways. This compound shows therapeutic potential for ischemic stroke treatment.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Microglial activation post-stroke releases toxic factors, exacerbating neuronal injury.
  • Salidroside demonstrates neuroprotective effects, but its anti-inflammatory mechanisms in microglia are unclear.

Purpose of the Study:

  • To investigate the molecular mechanisms of salidroside's anti-inflammatory activity in microglia.
  • To determine salidroside's effect on lipopolysaccharide (LPS)-stimulated microglial cell mobility and activation.

Main Methods:

  • Utilized BV2 microglial cells subjected to stretch injury and LPS stimulation.
  • Employed transwell migration assays to assess cell motility.
  • Measured chemokine production and analyzed the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways.

Main Results:

  • Salidroside significantly reduced BV2 microglial cell motility without cytotoxicity.
  • Suppressed LPS-induced chemokine production in a dose-dependent manner.
  • Inhibited LPS-induced NF-κB activation by blocking IκBα degradation and MAPK phosphorylation (p38, JNK, ERK1/2).

Conclusions:

  • Salidroside exhibits potent suppressive effects on microglial migration and activation.
  • The compound acts by inhibiting NF-κB and MAPK signaling pathways.
  • Salidroside holds therapeutic potential for ischemic stroke treatment by mitigating microglial-mediated inflammation.